BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 118 filers reported holding BIOXCEL THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.92 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $4,152,677 | -38.9% | 623,525 | +71.3% | 0.00% | -50.0% |
| Q1 2023 | $6,793,845 | -30.5% | 364,086 | -20.0% | 0.00% | -33.3% |
| Q4 2022 | $9,781,262 | +82.3% | 455,366 | +0.3% | 0.00% | +50.0% |
| Q3 2022 | $5,365,000 | -3.9% | 453,877 | +7.3% | 0.00% | 0.0% |
| Q2 2022 | $5,584,000 | -37.3% | 423,021 | -0.7% | 0.00% | -33.3% |
| Q1 2022 | $8,911,000 | +5.8% | 426,177 | +2.8% | 0.00% | +50.0% |
| Q4 2021 | $8,426,000 | -33.5% | 414,484 | -0.7% | 0.00% | -50.0% |
| Q3 2021 | $12,671,000 | +51.5% | 417,510 | +45.1% | 0.00% | +100.0% |
| Q2 2021 | $8,362,000 | -32.9% | 287,752 | -0.3% | 0.00% | -50.0% |
| Q1 2021 | $12,456,000 | -8.8% | 288,605 | -2.4% | 0.00% | 0.0% |
| Q4 2020 | $13,656,000 | +8.6% | 295,574 | +1.9% | 0.00% | -20.0% |
| Q3 2020 | $12,579,000 | -20.2% | 290,117 | -2.4% | 0.01% | -16.7% |
| Q2 2020 | $15,757,000 | +156.9% | 297,245 | +8.3% | 0.01% | +100.0% |
| Q1 2020 | $6,133,000 | – | 274,404 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Logos Global Management LP | 550,000 | $23,848,000 | 3.05% |
| SPHERA FUNDS MANAGEMENT LTD. | 269,300 | $11,677,000 | 1.15% |
| Avidity Partners Management LP | 538,000 | $23,328,000 | 1.08% |
| Knoll Capital Management, LLC | 20,000 | $867,000 | 0.71% |
| Maven Securities LTD | 200,000 | $8,610,000 | 0.71% |
| Prosight Management, LP | 29,800 | $1,292,000 | 0.62% |
| Artemis Investment Management LLP | 1,001,708 | $43,383,000 | 0.54% |
| Ikarian Capital, LLC | 150,000 | $6,504,000 | 0.47% |
| AlphaCentric Advisors LLC | 20,000 | $867,000 | 0.42% |
| MOODY ALDRICH PARTNERS LLC | 19,872 | $862,000 | 0.18% |